BONE MARROW METASTASES
Section snippets
Clinical Course
The clinical course of cancer patients with marrow metastases depends upon the other sites of metastatic disease. When bone marrow isthe predominant site of metastasis, patients who are untreated or who become refractory to therapy typically develop progressive pancytopenia. In that setting morbidity and mortality are most often due to myelosuppression-induced infection or bleeding or both.
Correlation Between Marrow Metastases and Clinical Outcome in the Standard Therapy Setting
Several clinical breast cancer studies have shown that patients with occult disease in the marrow have a
Routine Detection Methods
In addition to bone marrow aspirates and biopsies, the tests most widely used to detect or confirm marrow metastases in cancer patients include complete blood counts (CBC), radionuclide bone scans, and skeletal radiographs.
METHODS FOR ERADICATING CANCER CELLS FROM MARROW
High-dose therapy with autologous bone marrow support (ABMS) or, more recently, peripheral blood progenitor cell (PBPC) support, has become the treatment of choice for selected high-risk cancer patients. 23, 35, 41, 75 Autologous marrow may contain clonogenic tumor cells that could contribute to relapse of cancer if reinfused into the patient. 58 Marrow-supported intensive treatments are being employed with increasing frequency earlier in the course and stage of malignant disease. In this
Acute Myelogenous Leukemia (AML)
Many clinical studies suggest that marrow purging may benefit certain patients. Gorin et al 34 reported a higher disease-free survival rate in recipients of pharmacologically purged grafts when compared with unpurged autografts for AML patients in first complete remission. Using pharmacologically and immunologically purged marrow respectively, Yeager et al 79 and Ball et al 2 have reported disease-free survival rates for AML patients in second or third complete remission that appear to be
CONCLUSION
The question of whether bone marrow purging or purification is clinically necessary remains unanswered. A randomized trial comparing purged with unpurged marrow support is desirable to validate the importance of purging, Such trials have been very difficult to organize. Patient refusal, the large numbers of patients who would be required, the lack of agreement on the optimal purging regimen, and even the lack of agreement on the need to purge at all are obstacles that have thus far prevented
References (80)
- et al.
Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid cell-specific monoclonal antibodies
Blood
(1986) - et al.
Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma
Blood
(1991) - et al.
Bone marrow involvement by lobular carcinoma of the breast cannot be identified reliably by routine histologic examination alone
Hum Pathol
(1994) - et al.
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
Lancet
(1993) - et al.
Expression of the CD34 gene in vascular endothelial cells
Blood
(1990) - et al.
Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia
Blood
(1986) - et al.
Identification of a membrane glycoprotein associated with hematopoietic progenitor cells
Leuk Res
(1985) - et al.
Amifostine (WR-2721) shortens the engraftment period of 4 hydroperoxycyclophosphamide purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support
Blood
(1994) - et al.
Marrow purging in autologous bone marrow transplantation for T-lineage ALL: Efficacy of ex vivo treatment with immunotoxins and 4 hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells
Blood
(1987) - et al.
Human hematopoietic precursors in long-term cultures: Single CD34+ cells that lack detectable T cell, B cell, and myeloid antigens produce colony-forming cells when cultured with marrow stromal cells
J Exp Med
(1990)
Ribosome-inactivating proteins from plants: Properties and possible uses
Cancer Surv
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement
Cancer Res
Potential therapeutic role of cisplatin in autologous bone marrow transplantation: In vitro eradication of neuroblastoma cells from bone marrow
Br J Cancer
Autologous bone marrow transplant for children with AML in first complete remission: Use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse
Hum Gene Ther
International criteria for diagnosing, staging, and response to treatment in patients with neuroblastoma
J Clin Oncol
Use of CD34-positive autologous hematopoietic progenitors to support patients with breast cancer after high-dose chemotherapy
Blood
The value of bone marrow biopsy in breast cancer at the time of first relapse. A prospective study
Cancer
Bone marrow purging combining a monoclonal antibody against and VP-16
Exp Hematol
Highly purified CD34+ cells reconstitute hematopoiesis
Proc Am Soc Clin Oncol
Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells
J Immunol
Positive stem cell science
Bone marrow purging and processing Prog Clin Biol Res
Clinical significance of bcr-abl gene rearrangement by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
Blood
The Polymerase Chain Reaction
Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease
Am J Surg Pathol
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
J Clin Oncol
Polymerase chain reaction in the diagnosis of chromosomal breakpoints
Hematol Oncol Clin North Am
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen
Br J Cancer
Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-HC in combination with monoclonal antibodies and complement
Blood
Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (Asta Z 7557)
Exp Hematol
Osseous complications of malignancy
Reconstitution of hematopoiesis after bone marrow purging with ricin A chain immunotoxin
Transplantation
Polymerase chain reaction evaluation of bone marrow micrometastases in metastatic breast cancer
Breast Cancer Res Treat
Purging tumor cells from bone marrow by use of antibody and complement: A critical appraisal
J Natl Cancer Inst
Evidence for an anti-complementary factor associated with normal bone marrow cells
J Natl Cancer Inst
Immunomagnetic purging and autologous transplantation in stage D neuroblastoma
Bone Marrow Transplant
Instrumentation: Beyond the black box
The action of antibody and complement on mammalian cells
Ann NY Acad Sci
Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
N Engl J Med
Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma
J Clin Oncol
4-HC and vincristine as ex vivo marrow treatment for acute leukemia in second remission
Cited by (6)
Correlation of hematologic parameters with bone marrow and spleen uptake in FDG PET
2005, Revista Espanola de Medicina NuclearEvaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: Preclinical PET studies
2000, Journal of Nuclear MedicineDetection and significance of minimal residual disease from solid tumor malignancies in stem cell autografts
2000, Hematopoietic Stem Cell TransplantationMinimal residual disease in solid tumor malignancies: A review
1998, Journal of Hematotherapy and Stem Cell Research
Address reprint requests to Elizabeth J. Shpall, MD University of Colorado Health Sciences Center Campus Box B190 4200 East Ninth Avenue Denver, CO 80262
- *
From the Bone Marrow Transplant Program (EJS, CH, PC, UG, LH, SIB, MR, RBJ) and the Department of Pathology (WF), University of Colorado, Denver, Colorado; and the Division of Transplantation Medicine, Richland Memorial Hospital and the University of South Carolina, Columbia, South Carolina (APG)